Drug Trials 'Snapshots' Could Get Photoshopped, CDER Says
Executive Summary
Sponsors who disagree with how racial, gender and age-related demographic subgroup data for their products are described in public summaries may propose revisions and submit them for FDA consideration.
You may also be interested in...
US FDA's New Website May Facilitate Broader Outside Use Of Data
Redesigned FDA.gov is expected to allow application programming interfaces, which could allow other software to talk to the site and potentially use its data.
FDA Commissioner Candidate Gulfo Hates Breakthrough, Wants To Reevaluate User Fees
In an interview, Joseph Gulfo, former medtech industry CEO and vocal FDA critic, outlines his worldview and interest in pushing aggressively against increasing the FDA ‘body of law.’
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.